Novo Nordisk A/S
NONOF
Rank in Stocks
#110
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.21
Last synced: 2026-11-09
Market Cap
$180.56B
Change (1 day)
2.94%
Change (1 year)
-16.78%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Novo Nordisk A/S (NONOF)
Category
Healthcare
Operating Margin for Novo Nordisk A/S (NONOF)
Operating Margin as of November 2026 TTM: 43.13%
According to Novo Nordisk A/S's latest financial reports, its current operating margin (TTM) is 43.13%. At the end of 2025 the company had an operating margin of 41.30%.
Operating Margin history for Novo Nordisk A/S from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 43.13% | 4.43% |
| 2025 | 41.30% | -6.54% |
| 2024 | 44.19% | 0.07% |
| 2023 | 44.16% | 4.45% |
| 2022 | 42.28% | 1.51% |
| 2021 | 41.65% | -2.32% |
| 2020 | 42.64% | -0.86% |
| 2019 | 43.01% | 1.80% |
| 2018 | 42.25% | -3.63% |
| 2017 | 43.84% | 1.18% |
| 2016 | 43.33% | -5.41% |
| 2015 | 45.81% | 17.95% |
| 2014 | 38.84% | 3.08% |
| 2013 | 37.68% | -0.24% |
| 2012 | 37.77% | 12.01% |
| 2011 | 33.72% | 8.49% |
| 2010 | 31.08% | 6.29% |
| 2009 | 29.24% | 7.66% |
| 2008 | 27.16% | 27.03% |
| 2007 | 21.38% | -9.14% |
| 2006 | 23.53% | -1.75% |
| 2005 | 23.95% | -0.42% |
| 2004 | 24.05% | -0.04% |
| 2003 | 24.06% | 1.31% |
| 2002 | 23.75% | 0.64% |
| 2001 | 23.60% | 15.74% |
| 2000 | 20.39% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 46.07% | -98.93% |
US
|
|
| 25.70% | -99.40% |
US
|
|
| 35.53% | -99.18% |
US
|
|
| 16.24% | -99.62% |
US
|
|
| 31.92% | -99.26% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Novo Nordisk A/S's operating margin
What is Novo Nordisk A/S's operating margin?
Novo Nordisk A/S's operating margin is 43.13%, as of Nov 2026.
What was Novo Nordisk A/S's operating margin in 2025?
In 2025, Novo Nordisk A/S's operating margin was 41.30%, compared with 44.19% in 2024.
How has Novo Nordisk A/S's operating margin changed since 2020?
From 2020 to 2025, Novo Nordisk A/S's operating margin was highest in 2024 (44.19%) and lowest in 2025 (41.30%).
How does Novo Nordisk A/S's operating margin compare with similar companies?
Novo Nordisk A/S's operating margin (43.13%) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Eli Lilly and Company, with 46.07%.